SCHEMBL4072138

SCHEMBL4072138

C[C@H](O)c1ccccc1S(=O)(=O)c1ccc2cc(-c3ccc(F)cc3F)ccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.57
HTR2C P28335 3/20 0.57
KCNH2 Q12809 2/20 0.57
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
MMP2 P08253 4/20 0.41
MMP9 P14780 4/20 0.41
MMP8 P22894 4/20 0.41
MMP12 P39900 4/20 0.41
MMP13 P45452 4/20 0.41
MMP14 P50281 4/20 0.41
MMP16 P51512 4/20 0.41
MMP1 P03956 2/20 0.41
FEN1 P39748 7/20 0.40
ALOX5AP P20292 7/20 0.40
MMP3 P08254 3/20 0.39
PTGES2 Q9H7Z7 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4072974 1.00 HTR2A (0.57) HTR2AHTR2CKCNH2AKR1C3AKR1C2
SCHEMBL4075351 0.90 HTR2A (0.54) HTR2AHTR2CKCNH2AKR1C3AKR1C2
SCHEMBL4075235 0.88 HTR2A (0.66) HTR2AHTR2CKCNH2MMP2MMP9
SCHEMBL4075238 0.88 HTR2A (0.66) HTR2AHTR2CKCNH2MMP2MMP9
SCHEMBL4067027 0.88 HTR2A (0.66) HTR2AHTR2CKCNH2MMP2MMP9
SCHEMBL4076542 0.81 HTR2A (0.55) HTR2AHTR2CKCNH2MMP2MMP9
SCHEMBL4076311 0.79 HTR2A (0.59) HTR2AHTR2CKCNH2AKR1C3AKR1C2
SCHEMBL4077131 0.79 HTR2A (0.42) HTR2AHTR2CKCNH2FEN1ALOX5AP
SCHEMBL4073507 0.78 HTR2A (0.44) HTR2AHTR2CKCNH2FEN1ALOX5AP
SCHEMBL4067382 0.75 HTR2A (0.54) HTR2AHTR2CKCNH2MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US claimed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US claimed
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US disclosed
EP-1824817-B1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME (GB) 2009-02-04 EP disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A HTR2A 1/4885HTR2C 2/4885KCNH2 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.